| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19ClN2O4 |
| Molecular Weight | 362.807 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCNC(=O)C2=CN=CC=C2
InChI
InChIKey=MCECKJXCBZXVJI-UHFFFAOYSA-N
InChI=1S/C18H19ClN2O4/c1-18(2,25-15-7-5-14(19)6-8-15)17(23)24-11-10-21-16(22)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3,(H,21,22)
| Molecular Formula | C18H19ClN2O4 |
| Molecular Weight | 362.807 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Picafibrate is clofibrate derivative. It is a hypocholesteraemic agent. Fibrates reduce plasma triglycerides by inhibiting their hepatic synthesis and increasing their catabolism. These effects are due to activation of peroxisome proliferator-activated receptors (PPAR alpha) and induction of the over-expression of genes containing a peroxisome proliferator response element (PPRE) in their promoter.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
